# Melanoma: Assessment and Management - Committee Meeting 6



Date: 26<sup>th</sup> January 2021

Location: Zoom

Minutes: Final

Committee members present:		
Andrew Molyneux	Chair	Present for all
Guy Burkill	Radiologist	Present for all
Dharmisha Chauhan	Pharmacist	Present for all
Susan Cheetham	Lay person	Present for all
Fiona Collier	GP	Present for all
Gillian Godsell	Clinical nurse specialist	Present for all
Sarah Hemington-Gorse	Plastic Surgeon	Present for all
lan James	Lay person	Present for all
Lynne Jamieson	Histopathologist	Present for all
Stephen Keohane	Dermatologist	Present for all
John Lear	Dermatologist	Present from 15:42
Christine Parkinson	Medical Oncologist	Present from 09:45
Howard Peach	Plastic Surgeon	Present for all
Saskia Reeken	Clinical nurse specialist	Present for all
Myles Smith	General Surgeon	Present for all
Delia Sworm	Oncology nurse specialist	Present for all
Steven Watkins	Oncologist	Present for all

In attendance:		
Steph Armstrong	NICE Technical Adviser, Health Economics	Present for all
Victoria Axe	NICE Guideline Commissioning Manager	Present for all
Becky Chadwick	NICE Project Manager	Present for all
Jenny Craven	NICE Information Specialist	Present for all
Brett Doble	NICE Technical Adviser, Health Economics	Present for all
Jackie Durkin	NICE Administrator	Present until 10:00
Tom Jarrett	NICE Technical Analyst	Present for all
Jon Littler	NICE Observer	Present until 14:30
Vonda Murray	NICE Programme Manager	Present until 12:15
Caroline Mulvihill	NICE Technical Analyst	Present for all

Vonda Murray	NICE Programme Manager	Present until 12:15
--------------	------------------------	---------------------

Apologies:	
William Bolland	GP
Sophie Wilne	Paediatric and adolescent oncologist
Jeremy Dietz	NICE Technical Analyst, Health Economics
Sarah Palombella	NICE Medical Editor
Sue Spiers	NICE Associate Director

# Item 1

- Welcome
- DOIs
- Minutes from the last meeting

Andy Molyneux (the Chair) welcomed the committee members and attendees to the sixth committee meeting for the 'Melanoma: Assessment and Management' guideline. Apologies were noted as listed above.

Committee members were asked to declare any new interests that had occurred since the last meeting. No new interests were declared.

The minutes from committee meetings 4 and 5 were approved as an accurate record of proceedings.

# Item 2

• Review question 2.1(a): additional clinical evidence

NICE Technical Analyst Tom Jarratt (TJ) presented additional clinical evidence for RQ 2.1a on predicting SLNB positivity in thin melanomas.

The Chair thanked TJ for his presentation and invited the committee to ask questions about the evidence and any impact on the recommendations.

#### Item 3

• Review question 2.1(b): clinical evidence

NICE Technical Analyst Tom Jarratt (TJ) presented the clinical evidence for RQ 2.1b on imaging to detect involved lymph nodes and distant metastases.

The Chair thanked TJ for his presentation and invited comments and questions from the committee on the clinical evidence.

# Item 4

• Review question 2.1(b): health economic evidence

NICE Technical Adviser (Health Economics) Steph Armstrong gave a presentation on the existing health economic evidence for RQ 2.1(b) on imaging to detect involved lymph nodes and distant metastases, and invited the committee to provide comments and feedback.

The Chair thanked SA for her presentation and the committee for their feedback.

# Item 5

• Review question 6.2: clinical evidence

NICE Technical Analyst Yolanda Martinez gave a presentation of the clinical evidence for RQ6.2: What is the diagnostic accuracy of body imaging for re-staging during the follow-up of people with stage IIC (with no sentinel lymph node biopsy) and stage III melanoma?

The Chair thanked YM for her presentation and invited comments and feedback from the committee.

Item 6

• Review question 6.2: health economic evidence and planned HE model

NICE Technical Adviser (Health Economics) Steph Armstrong gave a presentation on the existing health economic evidence and an overview of the planned health economic model for RQ 6.2: What is the diagnostic accuracy of body imaging for re-staging during the follow-up of people with stage IIC (with no sentinel lymph node biopsy) and stage III melanoma?

The Chair thanked SA for her presentation and the committee for their questions and feedback.

Item 7

• AOB summary and next steps

The Chair thanked the committee for their contribution, summarised the main actions from the day and asked for items of any other business.

As there was no further business, the Chair highlighted the time of the next meeting and brought this meeting to a close.

Date of next meeting: 27<sup>th</sup> January 2021

Location of next meeting: Zoom